Caris Life Sciences (NASDAQ:CAI) Price Target Cut to $32.00 by Analysts at BTIG Research

Caris Life Sciences (NASDAQ:CAI) had its price objective trimmed by BTIG Research from $38.00 to $32.00 in a report released on Friday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on CAI. Piper Sandler initiated coverage on shares of Caris Life Sciences in a report on Friday, April 10th. They issued a “neutral” rating and a $21.00 price target for the company. Robert W. Baird upped their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, February 27th. Canaccord Genuity Group cut their price target on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a report on Friday, March 13th. Jefferies Financial Group initiated coverage on shares of Caris Life Sciences in a report on Monday, April 13th. They issued a “buy” rating and a $28.00 price target for the company. Finally, Wall Street Zen downgraded shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.56.

Caris Life Sciences Stock Down 18.6%

CAI stock opened at $16.15 on Friday. The firm has a market capitalization of $4.56 billion and a P/E ratio of -2.12. The business has a 50-day moving average of $19.15. Caris Life Sciences has a fifty-two week low of $15.71 and a fifty-two week high of $42.50. The company has a quick ratio of 7.35, a current ratio of 7.85 and a debt-to-equity ratio of 0.66.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.27. Caris Life Sciences had a net margin of 3.75% and a return on equity of 102.71%. The business had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. During the same quarter in the prior year, the company posted ($1.73) earnings per share. The company’s quarterly revenue was up 125.4% compared to the same quarter last year. Equities analysts anticipate that Caris Life Sciences will post 0.12 EPS for the current year.

Institutional Trading of Caris Life Sciences

A number of hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. lifted its stake in Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock valued at $248,377,000 after buying an additional 1,180,200 shares in the last quarter. Braidwell LP lifted its stake in Caris Life Sciences by 6.8% during the fourth quarter. Braidwell LP now owns 7,816,142 shares of the company’s stock valued at $210,880,000 after buying an additional 500,000 shares in the last quarter. PointState Capital LP lifted its stake in Caris Life Sciences by 73.0% during the fourth quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after buying an additional 2,834,986 shares in the last quarter. Orbimed Advisors LLC lifted its position in shares of Caris Life Sciences by 2.7% in the fourth quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company’s stock worth $84,070,000 after purchasing an additional 81,153 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Caris Life Sciences by 185.0% in the fourth quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock worth $65,974,000 after purchasing an additional 1,587,176 shares in the last quarter.

Caris Life Sciences News Summary

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Caris reported strong Q1 2026 results, with total revenue rising 79% year over year to $216.2 million, signaling continued demand for its molecular profiling services. Caris Life Sciences Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company submitted an application to New York State health regulators for authorization to perform Caris Assure blood-based testing on New York specimens, a potentially meaningful commercial expansion for its diagnostic platform. Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization
• Positive Sentiment: Despite lowering price targets, Citigroup, JPMorgan, and BTIG all kept bullish ratings on CAI, suggesting analysts still see substantial upside from current levels. Benzinga analyst update
• Neutral Sentiment: Investors are still parsing the earnings call transcript and presentation for details on profitability, margin trends, and whether management’s full-year guidance is achievable. Caris (CAI) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Coverage focused on why the stock is down reflects broader concern that valuation remains elevated and that the market may be reacting more to expectations and guidance than to the strong revenue beat. Why Caris Life Sciences, Inc.’s (CAI) Stock Is Down 18.04%
• Negative Sentiment: Multiple analysts cut their price targets after the report, including Citigroup to $28, JPMorgan to $30, and BTIG to $32, which may have weighed on sentiment even though all maintained positive ratings. Analyst price target changes

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.